Clene Reports Q3 2026 Results, $3.9 Million Net Income

Clene reported Q3 2026 revenue of $56,000 and net income of $3.9 million, improving from a $8.8 million loss in the prior year. The company's operating loss was $6.3 million, with net income boosted by a $10.9 million favorable change in warrant and derivative liabilities. Clene submitted an NDA for accelerated approval of CNM-Au8 for ALS, with a Phase 3 trial planned for Q2 2027. The company has $9.9 million in cash and expects resources to last through mid-Q1 2027.

Original reporting
Published Nov 4, 2026, 1:43 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 1:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Clene Reports Q3 2026 Results, $3.9 Million Net Income — source image
Decision brief

The 30-second read

$CLNNBullishLow
01

Why it matters

The earnings surprise could trigger short covering and modest buying in the thinly‑traded stock, but the small scale limits broader market impact.

02

Market read

Microcap earnings surprise with modest cash runway; limited but actionable for niche traders.

03

What to watch

The favorable shift in warrant and derivative liabilities contributed significantly to net income and may not repeat.

Relevance 6/10Novelty 7/10Timing: after‑hours release

Background

Clene Inc. (CLNN) filed an 8‑K reporting its Q3 2026 results, showing a profit swing and cash sufficient through mid‑Q1 2027, and disclosed an NDA for accelerated FDA approval of its ALS therapy.

Company-level read

Ticker impact

$CLNNBullishMedium confidence
Context

Clene reported Q3 2026 revenue of $56,000 and net income of $3.9 million, a swing from a loss a year earlier.

Expected impact

modest upside as market prices in the profit swing and cash runway through Q1 2027

Evidence & confidence

The company turned a loss into profit and disclosed sufficient cash to fund operations, which may attract short-covering and speculative buying in a thinly‑traded microcap.

Market effects

Limited impact; biotech microcaps may see slight interest from investors seeking earnings surprises.

Primarily U.S. OTC/OTC‑Q market; no broader regional effect.

Minimal; the news is confined to the company and does not affect global markets.

Counterpoint

Given the tiny revenue base, the profit may be a one‑off accounting effect rather than sustainable growth.

Key entities

  • Clene Inc.

    Biotech firm reporting Q3 2026 earnings and filing an NDA for ALS therapy.

Related articles

$CLNNHigh

CLENE REPORTS Third QUARTER 2026 FINANCIAL RESULTS

Clene Inc. (CLNN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CLENE REPORTS Third QUARTER 2026 FINANCIAL RESULTS AND RECENT OPERATING HIGHLIGHTS ● Submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in October 2026 seeking accelerated approval for CNM-Au8 ® in amyotrophic lateral sclerosis (ALS